.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cipla
Boehringer Ingelheim
Accenture
US Army
Argus Health
Farmers Insurance
Merck
Medtronic
QuintilesIMS

Generated: November 21, 2017

DrugPatentWatch Database Preview

Daiichi Sankyo Company Profile

« Back to Dashboard

What is the competitive landscape for DAIICHI SANKYO, and when can generic versions of DAIICHI SANKYO drugs launch?

DAIICHI SANKYO has eleven approved drugs.

There are five US patents protecting DAIICHI SANKYO drugs.

There are two hundred and fifty-nine patent family members on DAIICHI SANKYO drugs in thirty-six countries and forty-nine supplementary protection certificates in ten countries.

Summary for Daiichi Sankyo

International Patents:259
US Patents:5
Tradenames:9
Ingredients:9
NDAs:11
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-001Jan 8, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
MORPHABOND ER
morphine sulfate
TABLET, EXTENDED RELEASE;ORAL206544-001Oct 2, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Daiichi Sankyo Inc
MORPHABOND ER
morphine sulfate
TABLET, EXTENDED RELEASE;ORAL206544-003Oct 2, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
EVOXAC
cevimeline hydrochloride
CAPSULE;ORAL020989-002Jan 11, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe
Daiichi Sankyo
BENICAR HCT
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL021532-005Jun 5, 2003ABRXYesYes► Subscribe► Subscribe ► Subscribe
Daiichi Sankyo
AZOR
amlodipine besylate; olmesartan medoxomil
TABLET;ORAL022100-001Sep 26, 2007ABRXYesNo► Subscribe► Subscribe ► Subscribe
Daiichi Sankyo Inc
MORPHABOND ER
morphine sulfate
TABLET, EXTENDED RELEASE;ORAL206544-002Oct 2, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
CAPSULE;ORAL021141-001May 26, 2000DISCNNoNo► Subscribe► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
TABLET;ORAL021176-001May 26, 2000RXYesYes► Subscribe► SubscribeY► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-003Jan 8, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Daiichi Sankyo

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo Inc
EVOXAC
cevimeline hydrochloride
CAPSULE;ORAL020989-002Jan 11, 2000► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
TABLET;ORAL021176-001May 26, 2000► Subscribe► Subscribe
Daiichi Sankyo
BENICAR
olmesartan medoxomil
TABLET;ORAL021286-004Apr 25, 2002► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
FOR SUSPENSION;ORAL022362-001Oct 2, 2009► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
CAPSULE;ORAL021141-001May 26, 2000► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
TABLET;ORAL021176-001May 26, 2000► Subscribe► Subscribe
Daiichi Sankyo
BENICAR
olmesartan medoxomil
TABLET;ORAL021286-003Apr 25, 2002► Subscribe► Subscribe
Daiichi Sankyo
TRIBENZOR
amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL200175-003Jul 23, 2010► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
TABLET;ORAL021176-001May 26, 2000► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
TABLET;ORAL021176-001May 26, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for DAIICHI SANKYO drugs

Drugname Dosage Strength Tradename Submissiondate
colesevelam hydrochloride
Powder for Oral Suspension1.875 g/Packet and 3.75 g/Packet
WELCHOL
4/9/2010
colesevelam hydrochloride
Tablets625 mg
WELCHOL
7/1/2009
cevimeline hydrochloride
Capsules30 mg
EVOXAC
2/27/2009
amlodipine besylate and olmesartan medoxomil
Tablets10 mg/20 mg and 5 mg/40 mg
AZOR
3/31/2008
amlodipine besylate and olmesartan medoxomil
Tablets5 mg/20 mg and 10 mg/40 mg
AZOR
2/11/2008
olmesartan medoxomil and hydrochlorothiazide
Tablets20 mg/12.5 mg
BENICAR HCT
5/11/2007
olmesartan medoxomil and hydrochlorothiazide
Tablets40 mg/12.5 mg and 40 mg/25 mL
BENICAR HCT
2/15/2007
olmesartan medoxomil
Tablets5 mg, 20 mg and 40 mg
BENICAR
4/25/2006

Non-Orange Book Patents for Daiichi Sankyo

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,646,171 Angiotensin II antagonist 1-biphenylmethylimidazole compounds and their therapeutic use► Subscribe
8,377,428Low salt forms of polyallylamine► Subscribe
7,342,014Diamine derivatives► Subscribe
9,707,296Pharmaceutical composition► Subscribe
7,541,024Low salt forms of polyallylamine► Subscribe
7,261,880Methods of treating Syndrome X with aliphatic polyamines► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Daiichi Sankyo Drugs

Country Document Number Estimated Expiration
China1121859► Subscribe
Cyprus1113054► Subscribe
China100545160► Subscribe
JapanH0578328► Subscribe
Australia2008286914► Subscribe
South Korea20040018358► Subscribe
Japan5170932► Subscribe
Norway2003009► Subscribe
Denmark1923064► Subscribe
Portugal1923064► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Daiichi Sankyo Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009 00015Denmark► SubscribePRODUCT NAME: EN KOMBINATION AF OLMESARTANMEDOXOMIL, EVT. I FORM AF ET FARMACEUTISK ACCEPTABELT SALT OG AMLODIPIN-BESILAT; NAT. REG. NO/DATE: MT 42061, 42062, 42063 20081120; FIRST REG. NO/DATE: NL RVG 100984 20080819
0760Netherlands► SubscribePRODUCT NAME: EDOXABAN, EEN ZOUT DAARVAN, EEN SOLVAAT DAARVAAN OF EEN N-OXIDE DAARVAN, IN HET BIJZONDER EDOXABAN TOSYLAAT; REGISTRATION NO/DATE: EU/1/15/993 20150619
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
00528Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN HYDROCHLOORTHIAZIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; NATL. REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION: CH 61678 01-05 20110705
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
C/GB11/010United Kingdom► SubscribePRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK
00445Netherlands► SubscribePRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
C0048France► SubscribePRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
C/GB04/031United Kingdom► SubscribePRODUCT NAME: COLESEVELAM HYDROCHLORIDE; REGISTERED: UK EU/1/03/268/001-003 20040310
330Luxembourg► SubscribeCERTIFICATE TITLE: UNE COMBINAISON D'OLMESARTAN MEDOXOMIL, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET D'HYDROCHLOROTHIAZIDE (OLMETEC PLUS)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Citi
US Army
Colorcon
Daiichi Sankyo
Accenture
Farmers Insurance
Merck
Chinese Patent Office
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot